patent/CN-105949158-A

http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-105949158-A

Outgoing Links

Predicate	Object
assignee	http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_12a135a933620c99beab01d4ac785d25
classificationCPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-655 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D309-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-351
classificationIPCInventive	http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-351 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H15-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H13-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7024 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H1-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-7012 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H13-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D309-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-655
filingDate	2010-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor	http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_dd5034cca2ecdde7b629693d9c3fea13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_795b84d4a40e9c53f790bb76d6c241ca http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a7ca433ae43863d810186e656e37b980 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4e5466c6b72d4b4447d6bd4abf7ec10b
publicationDate	2016-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber	CN-105949158-A
titleOfInvention	2,3-Fluoroglycosides as neuraminidase inhibitors and their use as antiviral agents
abstract	Compounds of general structural formula (I) for use in the treatment or prophylaxis of viral infections, especially viral influenza are provided. Pharmaceutical formulations thereof and methods for their preparation are also described. The therapeutic effect is achieved by inhibiting viral neuraminidase, also known as viral sialidase. These neuraminidases are classified in the GH34 family of viral enzymes.
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-114190092-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106986901-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-106986901-B
priorityDate	2009-07-15-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type	http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate	Subject
isCitedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-9523157-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010029302-A2
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID468101819 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467787587 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID467864182

Total number of triples: 41.